Clinical Trial

Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of cholangiocarcinoma (CCA) at 12 months after surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-25.
Trial Details
NCT Number NCT06341764
Lead Sponsor National Cancer Institute, Naples
Conditions Cholangiocarcinoma
Enrollment 38 participants
Start Date 2023-09-01
Primary Completion 2025-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2024-11-07